✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Chiauranib is an investigational drug.
There have been 13 clinical trials for Chiauranib. The most recent clinical trial was a Phase 2 trial, which was initiated on July 1st 2021.
The most common disease conditions in clinical trials are Small Cell Lung Carcinoma, Lung Neoplasms, and Ovarian Neoplasms. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd., Medelis Inc., and H & J CRO International, Inc.
There is one US patent protecting this investigational drug.
Recent Clinical Trials for Chiauranib
|Mass Balance Study of [14C]Chiauranib||Chipscreen Biosciences, Ltd.||N/A|
|Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers||H & J CRO International, Inc.||Phase 1|
|Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy Volunteers||Chipscreen Biosciences, Ltd.||Phase 1|
Top disease conditions for Chiauranib
Top clinical trial sponsors for Chiauranib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Chiauranib||See Plans and Pricing||Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors||Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, CN)||See Plans and Pricing|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|